Amplify Weight Loss Drug & Treatment ETF (THNR)
- Expense ratio0.58%
- Net assets$5.7M
- Dividend yield1.70%
- 1-year return+2.90%
- Holdings21
THNR ETF price chart
THNR quote & trading statistics
THNR performance
Total return · as of October 18, 2026- YTD-4.17%
- 1 year+2.90%
- 1Y volatility
- 16.20%
- 3Y volatility
- 0.00%
- 3Y Sharpe ratio
- 0.00
Returns include reinvested distributions; 3-, 5- and 10-year figures are annualized.
THNR top 10 holdings
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | LLY | Eli Lilly and Company | 11.53% |
| 2 | NVO | Novo Nordisk A/S | 9.26% |
| 3 | AMGN | Amgen Inc | 6.17% |
| 4 | ROP | Roche Holding AG | 5.98% |
| 5 | GILD | Gilead Sciences Inc | 5.87% |
| 6 | ABBV | AbbVie Inc | 5.83% |
| 7 | AZN | AstraZeneca PLC | 5.81% |
| 8 | PFE | Pfizer Inc | 5.65% |
| 9 | REGN | Regeneron Pharmaceuticals Inc | 5.16% |
| 10 | 1093 | CSPC Pharmaceutical Group Ltd | 5.01% |
The top 10 holdings make up 66.3% of the fund (21 holdings in total). As of October 18, 2026.
About Amplify Weight Loss Drug & Treatment ETF
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.
THNR ETF FAQ
What is the THNR expense ratio?
Amplify Weight Loss Drug & Treatment ETF has a net expense ratio of 0.58%, or $58.00 a year for every $10,000 invested.
How much money is in THNR?
Amplify Weight Loss Drug & Treatment ETF has about $5.7M in net assets.
What are the top holdings of THNR?
The largest positions in THNR are Eli Lilly and Company (11.53%), Novo Nordisk A/S (9.26%), Amgen Inc (6.17%). The fund holds 21 securities in total.
How has THNR performed?
THNR returned +2.90% over the past year, including reinvested distributions.
Does THNR pay dividends?
THNR has a dividend yield of 1.70%.
When was THNR launched?
Amplify Weight Loss Drug & Treatment ETF began trading on May 20, 2024.
ETFs similar to THNR
Funds that track the same index or whose top-10 holdings overlap most with THNR's. Overlap: shared top-10 weight as a share of the larger top-10 total of the two funds.
| Symbol | Fund | Overlap | Expense ratio | Net assets | 1-year return |
|---|---|---|---|---|---|
| THNR | Amplify Weight Loss Drug & Treatment ETF | — | 0.58% | $5.7M | +2.90% |
| PBPH | Portfolio Building Block World Pharma and… | 62% | — | $1.09B | — |
| OZEM | Roundhill Glp-1 & Weight Loss ETF | 51% | 0.58% | $53.8M | +5.15% |